EUVIMEDEUVIMED entdecken
Open Access

Ovarian function in female survivors of high‐risk neuroblastoma

Lauren Jimenez-Kurlander, Amelia DeRosa, Caroline E Kostrzewa, Chaya S Moskowitz, Kimberly Bogardus, Zoltan Antal, Suzanne Wolden iD, Michael P La Quaglia iD, Ellen M Basu, Fiorella Iglesias Cardenas, Kim Kramer, Brian H Kushner und 3 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Lauren Jimenez-Kurlander und 14 weiteren Autor:innen. Beteiligte Einrichtung: Boston Children's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Cancer Survivors, Primary Ovarian Insufficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Meg-Berte Owen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Data on ovarian function in neuroblastoma survivors are limited. We sought to determine the prevalence of ovarian dysfunction in a cohort of high‐risk neuroblastoma survivors and compare outcomes among survivors treated with and without autologous stem cell rescue (ASCR) preceded by myeloablative chemotherapy.

Methods

Retrospective review of female survivors of high‐risk neuroblastoma ≥5 years from diagnosis, diagnosed between 1982 and 2014, and followed in a tertiary cancer center. Participants were divided into two groups: individuals treated with conventional chemotherapy ± radiation (“non‐ASCR”) ( n = 32) or with chemotherapy ± radiation followed by myeloablative chemotherapy with ASCR (“ASCR”) ( n = 51). Ovarian dysfunction was defined as follicle‐stimulating hormone ≥15 mU/mL, while premature ovarian insufficiency (POI) was defined as persistent ovarian dysfunction requiring hormone replacement therapy. Poisson models were used to determine prevalence ratios of ovarian dysfunction and POI.

Results

Among 83 females (median attained age: 19 years [range, 10‐36]; median follow‐up: 15 years [range, 7‐36]), 49 (59%) had ovarian dysfunction, and 34 (41%) developed POI. Survivors treated with ASCR were 3.2‐fold more likely to develop ovarian dysfunction (95% CI: 1.8‐6.0; p < 0.001) and 4.5‐fold more likely to develop POI (95% CI: 1.7‐11.7; p = 0.002) when compared with those treated with conventional chemotherapy, after adjusting for attained age. Two participants in the non‐ASCR group and six in the ASCR group achieved at least one spontaneous pregnancy.

Discussion

Ovarian dysfunction is prevalent in female high‐risk neuroblastoma survivors, especially after ASCR. Longitudinal follow‐up of larger cohorts is needed to inform counseling about the risk of impaired ovarian function after neuroblastoma therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaCancer SurvivorsPrimary Ovarian InsufficiencyHumansFemaleAdolescentRetrospective StudiesAdultChildYoung AdultFollow-Up StudiesOvaryAntineoplastic Combined Chemotherapy ProtocolsTransplantation, Autologous

Stichwörter der Autor:innen

autologous hematopoietic stem cell rescuechildhood cancer survivorsfertility preservationneuroblastomaovarian function

Autor:innen und Institutionen

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Weill Cornell Medical College, New York, New York, USA.
  • Department of Radiation Oncology, Memorial Sloan Kettering, New York, New York, USA.

ORCID-Profile: Suzanne Wolden, Michael P La Quaglia, Shakeel Modak, Danielle Novetsky Friedman

Förderung

  • NCI NIH HHS
  • Meg-Berte Owen Foundation

Zitieren

APA

Jimenez-Kurlander, L., DeRosa, A., Kostrzewa, C. E., Moskowitz, C. S., Bogardus, K., Antal, Z., Wolden, S., La Quaglia, M. P., Basu, E. M., Cardenas, F. I., Kramer, K., Kushner, B. H., Cheung, N. V., Modak, S., & Friedman, D. N. (2024). Ovarian function in female survivors of high‐risk neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31181

Vancouver

Jimenez-Kurlander L, DeRosa A, Kostrzewa CE, Moskowitz CS, Bogardus K, Antal Z, et al. Ovarian function in female survivors of high‐risk neuroblastoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31181

BibTeX
@article{JimenezKurlander2024,
  author = {Jimenez-Kurlander, Lauren and DeRosa, Amelia and Kostrzewa, Caroline E and Moskowitz, Chaya S and Bogardus, Kimberly and Antal, Zoltan and Wolden, Suzanne and La Quaglia, Michael P and Basu, Ellen M and Cardenas, Fiorella Iglesias and Kramer, Kim and Kushner, Brian H and Cheung, Nai-Kong V and Modak, Shakeel and Friedman, Danielle Novetsky},
  title = {Ovarian function in female survivors of high‐risk neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31181}
}
Kostenlos starten →